NO975513D0 - 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel - Google Patents

3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel

Info

Publication number
NO975513D0
NO975513D0 NO975513A NO975513A NO975513D0 NO 975513 D0 NO975513 D0 NO 975513D0 NO 975513 A NO975513 A NO 975513A NO 975513 A NO975513 A NO 975513A NO 975513 D0 NO975513 D0 NO 975513D0
Authority
NO
Norway
Prior art keywords
hydroxypyridine
drug
preparation
carboxylic acid
acid amide
Prior art date
Application number
NO975513A
Other languages
English (en)
Other versions
NO309717B1 (no
NO975513L (no
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO975513D0 publication Critical patent/NO975513D0/no
Publication of NO975513L publication Critical patent/NO975513L/no
Publication of NO309717B1 publication Critical patent/NO309717B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO975513A 1996-12-04 1997-12-01 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse i legemiddel NO309717B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19650215A DE19650215A1 (de) 1996-12-04 1996-12-04 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (3)

Publication Number Publication Date
NO975513D0 true NO975513D0 (no) 1997-12-01
NO975513L NO975513L (no) 1998-06-05
NO309717B1 NO309717B1 (no) 2001-03-19

Family

ID=7813570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975513A NO309717B1 (no) 1996-12-04 1997-12-01 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse i legemiddel

Country Status (18)

Country Link
US (1) US6020350A (no)
EP (1) EP0846685B1 (no)
JP (1) JPH10168062A (no)
KR (1) KR19980063725A (no)
CN (1) CN1184104A (no)
AR (1) AR010328A1 (no)
AT (1) ATE214371T1 (no)
AU (1) AU743750B2 (no)
BR (1) BR9706129A (no)
CA (1) CA2223366A1 (no)
CZ (1) CZ383297A3 (no)
DE (2) DE19650215A1 (no)
HU (1) HUP9702345A2 (no)
NO (1) NO309717B1 (no)
NZ (1) NZ329299A (no)
PL (1) PL323517A1 (no)
SG (1) SG65705A1 (no)
TR (1) TR199701490A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306839B1 (en) 1998-09-16 2001-10-23 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl) phenyl acetamides with (derivatised) hydroxyalkyl derivatives on the pyridine ring
PL206415B1 (pl) 1999-07-20 2010-08-31 Dow Agrosciences Llc Heterocykliczny amid aromatyczny, kompozycja grzybobójcza heterocyklicznego amidu aromatycznego oraz sposób zwalczania lub zapobiegania zakażeniom grzybami
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) * 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
KR100934674B1 (ko) * 2006-03-30 2009-12-31 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
EP3026044B8 (en) 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
EP2496084B1 (en) 2009-11-06 2015-06-10 Aerpio Therapeutics Inc. Compositions and methods for treating colitis
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (no) 2011-06-06 2018-03-17
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
CN106132201A (zh) * 2014-01-23 2016-11-16 阿克比治疗有限公司 用于治疗眼部疾病的组合物和方法
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
KR102473897B1 (ko) * 2015-05-28 2022-12-06 니뽄 다바코 산교 가부시키가이샤 당뇨병성 신증을 치료 또는 예방하는 방법
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT201900021960A1 (it) * 2019-11-22 2021-05-22 Isagro Spa Composti ad attività fungicida, loro composizioni agronomiche e relativo metodo di preparazione
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
AU743750B2 (en) 2002-02-07
BR9706129A (pt) 1999-05-18
JPH10168062A (ja) 1998-06-23
KR19980063725A (ko) 1998-10-07
EP0846685A1 (de) 1998-06-10
US6020350A (en) 2000-02-01
CN1184104A (zh) 1998-06-10
EP0846685B1 (de) 2002-03-13
HU9702345D0 (en) 1998-03-02
MX9709438A (es) 1998-06-30
NO309717B1 (no) 2001-03-19
TR199701490A2 (xx) 1998-06-22
CA2223366A1 (en) 1998-06-04
DE59706602D1 (de) 2002-04-18
AR010328A1 (es) 2000-06-07
HUP9702345A2 (hu) 2002-11-28
AU4679297A (en) 1998-06-11
NO975513L (no) 1998-06-05
ATE214371T1 (de) 2002-03-15
CZ383297A3 (cs) 1998-06-17
NZ329299A (en) 1998-11-25
DE19650215A1 (de) 1998-06-10
PL323517A1 (en) 1998-06-08
SG65705A1 (en) 1999-06-22

Similar Documents

Publication Publication Date Title
NO975513D0 (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
DK1538160T3 (da) Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
NO993619D0 (no) Titandioksid, fremstilling og anvendelse derav
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HK1038346A1 (en) Sulfur substituted sulfonylaminocarboxylic acid nm-arylamides, their preparation, their use and pharmaceutical preparations comprising them
IS2076B (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
DK1119557T3 (da) Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5129A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
EE200200160A (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO981522L (no) Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister
IS6420A (is) Setnar Fenýl-píperazín afleiður, framleiðsla þeirra og notkun
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
NO951418D0 (no) Peptidderivater, deres fremstilling og anvendelse som terapeutika
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel
NO980471L (no) Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JUNE 2003